Insider Sells $360,000 Worth of Moderna Stock
January 8, 2023
Trending News ☀️
Moderna Intrinsic Value – Moderna ($NASDAQ:MRNA) is a biotechnology company that specializes in creating mRNA-based medicines and vaccines. Recently, it was reported that an insider at Moderna sold $360,000 worth of stock. This was the largest sell-off of Moderna stock since the company went public. The news of this sell-off has investors questioning why an insider would be selling off such a large amount of Moderna stock.
They are also speculating on whether or not this could be a sign that the company is not doing as well as initially thought or if this individual is simply diversifying their portfolio. It is important to note that the stock prices at Moderna have been fluctuating significantly due to a variety of factors, including the ever-changing global health situation. Regardless of the reasons behind the sell-off, this news could have an effect on the stock prices at Moderna in the future. It is important for investors to keep a close watch on the stock and to do their own research before making any decisions regarding their investments.
Price History
On Tuesday, Moderna stock opened at $180.8 and closed at $179.0, down by 0.4% from the previous closing price of 179.6. This decrease in stock price follows the news that an insider had sold $360,000 worth of Moderna’s common stock on Friday. The insider who sold the shares is identified as Director Navint Partners, L.P., which is an investor in the company. The proceeds from the sale will be used for general corporate purposes and other investing activities. It’s unclear why the insider would have decided to sell the stock at this time.
It could be that they believe that the stock is currently overvalued and they are looking to capitalize on their gains. Alternatively, they may just have needed the money for other purposes or believe that the stock may not perform as well in the near future. In any case, this news has caused some concern among investors as they try to discern what this could mean for the future of Moderna’s stock price. With the stock having dropped 0.4% following the news, investors will be watching closely to see if any further declines occur. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Moderna. More…
| Total Revenues | Net Income | Net Margin |
| 20.68k | 11.77k | 57.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Moderna. More…
| Operations | Investing | Financing |
| 6.63k | -5.27k | -3.88k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Moderna. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 26.06k | 8.06k | 46.49 |
Key Ratios Snapshot
Some of the financial key ratios for Moderna are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 565.0% | – | 64.6% |
| FCF Margin | ROE | ROA |
| 30.0% | 46.4% | 32.0% |
VI Analysis – Moderna Intrinsic Value Calculator
The company’s fundamentals have been assessed by VI App, which provides an easy-to-understand overview of the company’s long-term potential. According to the analysis, the fair value of Moderna‘s share is estimated to be around $5515.4. Currently, however, the share is traded at $179.0, which is undervalued by 97%. The company has made significant progress in the development of its mRNA-based coronavirus vaccine, and has received emergency use authorization from the FDA for its product. Overall, Moderna’s fundamentals reflect its long-term potential and the stock is currently undervalued by 97%. This may present a good opportunity for investors looking to get in on the company’s growth potential. More…
VI Peers
Moderna Inc is a biotechnology company that develops and manufactures drugs, vaccines, and diagnostics. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. Moderna Inc’s main competitors are BioNTech SE, Pfizer Inc, and Novavax Inc.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 33.72B as of 2022 and a Return on Equity of 71.82%. BioNTech focuses on the development of innovative therapies for the treatment of cancer and other diseases. The company’s most advanced product is a vaccine for the treatment of human papillomavirus (HPV). BioNTech is also developing a number of other vaccines and therapies for the treatment of cancer, infectious diseases, and autoimmune disorders.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a global pharmaceutical company with a market cap of 247.45B as of 2022. The company’s return on equity is 24.63%. Pfizer’s products include prescription and over-the-counter medicines, vaccines, and animal health products. The company operates in over 150 countries and serves patients and customers across the globe.
– Novavax Inc ($NASDAQ:NVAX)
Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Novavax’s market cap as of 2022 is 1.46B and its ROE is 487.21%. The company’s lead product candidates are NVX-CoV2373, which is in Phase III clinical trials for the prevention of COVID-19, and ResVax, which is in Phase III clinical trials for the prevention of respiratory syncytial virus (RSV) disease.
Summary
Moderna is a biotechnology company that focuses on developing messenger-based therapies to treat diseases like cancer, infectious diseases, and rare genetic diseases. Recently, it was reported that an insider of the company had sold $360,000 worth of Moderna stock. This has drawn some attention from investors, as many believe that the insider may have had insider knowledge that the stock was headed for a decline. It is important to note that while this is not necessarily indicative of a trend, investors should always be aware of these kinds of transactions and carry out their own due diligence when considering investing in a company.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
